LYRA THERAPEUTICS INC (LYRA) Stock Income Statement
NASDAQ:LYRA - Nasdaq - US55234L1052 - Common Stock - Currency: USD
| TTM (2025-3-31) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 1.19M | 1.53M | 1.56M | 1.36M | 290.00K | |||
| Operating Expenses | 46.35M | 62.27M | 67.09M | 56.35M | 43.90M | |||
| Research and Development | 30.40M | 43.77M | 48.03M | 38.80M | 29.69M | |||
| Selling, General, and Administrative Expenses | 15.95M | 18.50M | 19.06M | 17.56M | 14.21M | |||
| Operating Income | -45.16M | -60.73M | -65.53M | -54.99M | -43.62M | |||
| Interest Income/Expense | 2.16M | 2.95M | 4.50M | 1.04M | 100.00K | |||
| Other Income/Expense | N/A | N/A | N/A | N/A | N/A | |||
| Non Recurring Items | -36.50M | -35.62M | -1.59M | -1.32M | N/A | |||
| Income Before Taxes | -79.50M | -93.40M | -62.62M | -55.27M | -43.51M | |||
| Income Tax | 29.00K | 39.00K | 59.00K | 10.00K | N/A | |||
| Net Income | -79.53M | -93.44M | -62.68M | -55.28M | -43.51M | |||
| EBITDA | -44.70M | -60.26M | -65.25M | -53.92M | -42.62M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -60.68 | -71.74 | -62.92 | -91.41 | -167.52 | |||
| Non GAAP EPS | -60.00 | -71.50 | -62.50 | -87.50 | -167.50 | |||
| Statistics | ||||||||
| Profit Margin | -6711.39% | -6090.94% | -4023.11% | -4064.71% | -15003.45% | |||
| Operating Profit Margin | -3811.39% | -3959.13% | -4205.91% | -4043.38% | -15041.38% | |||
All data in USD